About XBiotech
XBiotech is a publicly listed company based in Austin (United States) founded in 2005 by John Simard. Therapeutic antibodies are developed for oncology, inflammation, and infectious diseases. It operates on a HealthTech model. The company has 92 employees. Its chief executive, as recorded, is John Simard. XBiotech offers products and services including True Humanâ„¢ Antibodies, Natrunixâ„¢, and Unmetixâ„¢. Its focus areas include Biotechnology and Therapeutic Antibodies. Its legal entity is XBiotech USA, INC. Similar companies include Moderna, BeiGene and Incyte; 2 of its 3 listed similar companies have raised funding.
Company details
XBiotech is engaged in the discovery and development of therapeutic antibodies derived from natural human immunity. True Human antibodies are utilized to address unmet medical needs in areas such as oncology, neurology, rheumatology, and infectious diseases. Innovative solutions are provided through a pioneering pipeline that harnesses the bodys immune system to combat harmful inflammation and other conditions. Research and manufacturing facilities are maintained in Austin, Texas, supporting clinical trials and advancements in biotechnology.
- Headquarters Austin, United States
- Employees 92
- Founders John Simard
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website xbiotech.com
- Social LinkedIn X Facebook
- Legal Name Xbiotech Inc.
- Net Profit-$45.54 M (USD)-18.19as on Dec 31, 2025
- EBITDA-$54 M (USD)-32.59as on Dec 31, 2025
- Employee Count92
Products & Services of XBiotech
XBiotech offers a comprehensive portfolio of products and services, including True Human™ Antibodies, Natrunix™, and Unmetix™.
Therapeutic antibodies are derived from natural human immunity.
Antibody therapy is developed for advanced colorectal cancer.
Novel cocktail is prepared for shingles therapy treatment.
People of XBiotech
20 people are tracked at XBiotech (8 in leadership, 12 in team); the tracked headcount is 92.
| Name | Role | Group |
|---|---|---|
John Simard | Founder & CEO | Leadership |
Sushma Shivaswamy | Chief Scientific Officer | Leadership |
Ashley Otero | Vice President of Clinical Operations | Leadership |
Michael Cavalier | Senior Director of Manufacturing | Leadership |
Queena Han, CPA. CGA | Vice President, Finance and Human Resources and Secretary (Principal Financial Officer) | Leadership |
Victor Rowell | Director Of IT | Leadership |
Tzu-Yu Kwan | Associate Director of Cell Line Development | Leadership |
Queena Han | Vice President of Finance and Human Resources and Secretary | Leadership |
William Amole | Manager of Downstream Manufacturing | Team |
Hana K. | Senior Scientist | Team |
Jeannine Jorpeland | Clinical Research Project Specialist | Team |
Ana Cláudia Boareto da Costa Cesar | Senior Scientist - Pharmacology and Toxicology | R&D | Team |
Vibhuti Rana | Scientist | Team |
Fuqu Hu | Senior Scientist | Team |
Young Man Kwon | Principal Scientist | Team |
David Medina | Manager - Upstream Manufacturing | Team |
Bingwen Liu | Scientist | Team |
Wenyi Wei | Accountant | Team |
Xinxian Hu | Financial Controller | Team |
Sahil Patel | Research Associate III | Team |
Complete people profiles for XBiotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of XBiotech
XBiotech is a publicly listed company on the NASDAQ with ticker symbol XBIT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Apr 2015
- Listed onNASDAQ: XBIT
- Listed entityXBiotech Inc.
- Exchange sectorHealth technology
- ISINCA98400H1029
- Share price$2.16 (-5.68% on the day) · 2026-10-13
- Market capitalisation$65.9M
- EPS (diluted, trailing year)$-1.48
- Volume (last session)78,446
Financials of XBiotech
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$45.5M | -$54.0M | |
| 2024 | -$38.5M | -$40.7M | |
| 2023 | -$24.6M | -$35.8M | |
| 2022 | $4.0M | -$32.9M | -$31.9M |
| 2021 | $18.4M | -$17.4M | -$22.4M |
Detailed financial statements for XBiotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to XBiotech
XBiotech has 3 listed similar companies in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed similar companies of XBiotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of XBiotech
The website of XBiotech (xbiotech.com) receives about 3.9K visits a month.
- Monthly visits3.9K
▲ 58.9% vs previous month
Websites whose visitors overlap most with XBiotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| vgxii.com | 100% | 2.9K | #6,447,856 | View details | |
seedbiotech.com | seedbiotech.com | 100% | – | ||
| phoenixbiotechnology.com | 99% | View details | |||
| cellingbiosciences.com | 95% | View details | |||
hope.bio | hope.bio | 94% | #5,286,702 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for XBiotech
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as XBiotech (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xbiotech
Complete news archive for XBiotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about XBiotech
XBiotech was founded in 2005.
XBiotech is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
John Simard is the CEO of XBiotech, as recorded in our data. They have also founded this company.
XBiotech has 92 employees.
XBiotech is engaged in the discovery and development of therapeutic antibodies derived from natural human immunity. True Human antibodies are utilized to address unmet medical needs in areas such as oncology, neurology, rheumatology, and infectious diseases. Innovative solutions are provided through a pioneering pipeline that harnesses the bodys immune system to combat harmful inflammation and other conditions. Research and manufacturing facilities are maintained in Austin, Texas, supporting clinical trials and advancements in biotechnology.
XBiotech offers True Humanâ„¢ Antibodies, Natrunixâ„¢, and Unmetixâ„¢.
Yes, XBiotech is publicly traded on NASDAQ under the ticker symbol XBIT.
XBiotech operates through Xbiotech Usa, Inc..